Archives of Clinical Infectious Diseases

Published by: Kowsar

What Is the Most Recent Evidence on the Prevention and Early Treatment of Invasive Fungal Infections in Nonneutropenic Critically Ill Patients?

Andrea Cortegiani 1 , * , Vincenzo Russotto 1 , Pasquale Iozzo 2 , Santi Maurio Raineri 1 and Antonino Giarratano 1
Authors Information
1 Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia Analgesia Intensive Care and Emergency, Pocliclinico P. Giaccone University of Palermo, Italy
2 General Intensive Care Unit, Policlinico P. Giaccone. University of Palermo, Italy
Article information
  • Archives of Clinical Infectious Diseases: October 2017, 12 (4); e12414
  • Published Online: September 24, 2017
  • Article Type: Review Article
  • Received: December 15, 2016
  • Revised: May 2, 2017
  • Accepted: September 19, 2017
  • DOI: 10.5812/archcid.12414

To Cite: Cortegiani A, Russotto V, Iozzo P, Raineri S M, Giarratano A. What Is the Most Recent Evidence on the Prevention and Early Treatment of Invasive Fungal Infections in Nonneutropenic Critically Ill Patients?, Arch Clin Infect Dis. 2017 ; 12(4):e12414. doi: 10.5812/archcid.12414.

Copyright © 2017, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Updated Evidence
3. Paradoxical Evidence
4. Guideline Recommendations
5. Conclusion
  • 1. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373(15):1445-56. doi: 10.1056/NEJMra1315399. [PubMed: 26444731].
  • 2. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9. doi: 10.1001/jama.2009.1754. [PubMed: 19952319].
  • 3. Cortegiani A, Russotto V, Raineri SM, Gregoretti C, De rosa FG, Giarratano A. Untargeted Antifungal Treatment Strategies for Invasive Candidiasis in Non-neutropenic Critically Ill Patients: Current Evidence and Insights. Curr fungal infect rep. 2017;11(3):84-91. doi: 10.1007/s12281-017-0288-3.
  • 4. Puig-Asensio M, Peman J, Zaragoza R, Garnacho-Montero J, Martin-Mazuelos E, Cuenca-Estrella M, et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med. 2014;42(6):1423-32. doi: 10.1097/CCM.0000000000000221. [PubMed: 24557426].
  • 5. Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in IGOI. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39(4):665-70. doi: 10.1097/CCM.0b013e318206c1ca. [PubMed: 21169817].
  • 6. De Rosa FG, Corcione S, Filippini C, Raviolo S, Fossati L, Montrucchio C, et al. The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards, (corrected). PLoS One. 2015;10(5):125149. doi: 10.1371/journal.pone.0125149. [PubMed: 25938486].
  • 7. Russotto V, Cortegiani A, Graziano G, Saporito L, Raineri SM, Mammina C, et al. Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria. Infect Drug Resist. 2015;8:287-96. doi: 10.2147/IDR.S48810. [PubMed: 26300651].
  • 8. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739-46. doi: 10.1093/cid/cis305. [PubMed: 22423135].
  • 9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640-5. doi: 10.1128/AAC.49.9.3640-3645.2005. [PubMed: 16127033].
  • 10. Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis. 2009;64(4):402-7. doi: 10.1016/j.diagmicrobio.2009.04.002. [PubMed: 19446982].
  • 11. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284-92. doi: 10.1093/cid/cit006. [PubMed: 23315320].
  • 12. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med. 2012;40(3):813-22. doi: 10.1097/CCM.0b013e318236f297. [PubMed: 22297630].
  • 13. Leroy O, Bailly S, Gangneux JP, Mira JP, Devos P, Dupont H, et al. Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care. 2016;6(1):2. doi: 10.1186/s13613-015-0103-7. [PubMed: 26743881].
  • 14. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. [PubMed: 23137135].
  • 15. Cortegiani A, Russotto V, Montalto F, Foresta G, Accurso G, Palmeri C, et al. Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol. 2014;14:9. doi: 10.1186/1471-2253-14-9. [PubMed: 24559080].
  • 16. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non neutropenic critically ill patients. Cochrane Database Syst Rev. 2006;(1):4920. doi: 10.1002/14651858.CD004920.pub2. [PubMed: 16437504].
  • 17. Knitsch W, Vincent JL, Utzolino S, Francois B, Dinya T, Dimopoulos G, et al. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis. 2015;61(11):1671-8. doi: 10.1093/cid/civ707. [PubMed: 26270686].
  • 18. Schuster MG, Edwards JJ, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149(2):83-90. [PubMed: 18626047].
  • 19. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58(9):1219-26. doi: 10.1093/cid/ciu074. [PubMed: 24550378].
  • 20. Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Raineri SM, et al. Antifungal agents for preventing fungal infections in non neutropenic critically ill patients. Cochrane Database Syst Rev. 2016;(1):4920. doi: 10.1002/14651858.CD004920.pub3. [PubMed: 26772902].
  • 21. Cortegiani A, Russotto V, Giarratano A. Associations of antifungal treatments with prevention of fungal infection in critically ill patients without neutropenia. JAMA. 2017;317(3):311-2. doi: 10.1001/jama.2016.16535. [PubMed: 28114533].
  • 22. Cortegiani A, Russotto V, Raineri SM, Giarratano A. Antifungal prophylaxis: update on an old strategy. Eur J Clin Microbiol Infect Dis. 2016;35(10):1719-20. doi: 10.1007/s10096-016-2699-4. [PubMed: 27344576].
  • 23. Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, et al. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU acquired sepsis, candida colonization, and multiple organ failure, the EMPIRICUS randomized clinical trial. JAMA. 2016;316(15):1555-64. doi: 10.1001/jama.2016.14655. [PubMed: 27706483].
  • 24. Cortegiani A, Russotto V, Giarratano A. Lessons from uncertainty on antifungal treatment in ICU. J Thorac Dis. 2017;9(4):390-1. doi: 10.21037/jtd.2017.03.65. [PubMed: 28523186].
  • 25. Cortegiani A, Russotto V, Raineri SM, Giarratano A. The paradox of the evidence about invasive fungal infection prevention. Crit Care. 2016;20(1):114. doi: 10.1186/s13054-016-1284-7. [PubMed: 27117474].
  • 26. Spec A, Shindo Y, Burnham CA, Wilson S, Ablordeppey EA, Beiter ER, et al. T cells from patients with Candida sepsis display a suppressive immunophenotype. Crit Care. 2016;20:15. doi: 10.1186/s13054-016-1182-z. [PubMed: 26786705].
  • 27. Russotto V, Cortegiani A, Raineri SM, Giarratano A. From bedside to bench: the missing brick for patients with fungal sepsis. Crit Care. 2016;20(1):191. doi: 10.1186/s13054-016-1378-2. [PubMed: 27323797].
  • 28. Cortegiani A, Russotto V, Raineri SM, Gregoretti C, Giarratano A. Dying with or because of invasive fungal infection? The role of immunity exhaustion on patient outcome. Turk J Anaesthesiol Reanim. 2016;44(6):285-6. doi: 10.5152/TJAR.2016.0013. [PubMed: 28058138].
  • 29. Posteraro B, Tumbarello M, De Pascale G, Liberto E, Vallecoccia MS, De Carolis E, et al. (1,3)-beta-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother. 2016;71(8):2262-9. doi: 10.1093/jac/dkw112. [PubMed: 27125554].
  • 30. Cortegiani A, Russotto V, Raineri SM, Giarratano A. Is it time to combine untargeted antifungal strategies to reach the goal of 'early' effective treatment?. Crit Care. 2016;20(1):241. doi: 10.1186/s13054-016-1404-4. [PubMed: 27515019].
  • 31. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky Zeichner L, et al. Clinical practice guideline for the management of candidiasis, 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):1-50. doi: 10.1093/cid/civ933. [PubMed: 26679628].
  • 32. Cortegiani A, Russotto V, Raineri SM, Gregoretti G, Giarratano A. Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why?. Crit Care. 2016;20(1):351. doi: 10.1186/s13054-016-1521-0. [PubMed: 27794360].
  • 33. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724-32. doi: 10.1093/cid/cit136. [PubMed: 23487382].
  • 34. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem?. Curr Opin Infect Dis. 2014;27(6):484-92. doi: 10.1097/QCO.0000000000000111. [PubMed: 25304391].
  • 35. Cortegiani A, Russotto V, Raineri SM, Gregoretti C, Giarratano A. Should we administer antifungal drugs before the diagnosis of invasive fungal infection in non neutropenic critically ill patients?. Turk J Anaesthesiol Reanim. 2016;44(6):276-8. doi: 10.5152/TJAR.2016.0010. [PubMed: 28058135].
  • 36. Bassetti M, Garnacho Montero J, Calandra T, Kullberg B, Dimopoulos G, Azoulay E, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017;43(9):1225-38. doi: 10.1007/s00134-017-4731-2. [PubMed: 28255613].
  • 37. De Rosa FG, Corcione S, Montrucchio G, Brazzi L, Di Perri G. Appropriate treatment of invasive candidiasis in ICU, timing, colonization index, candida score and biomarkers, towards de escalation?. Turk J Anaesthesiol Reanim. 2016;44(6):279-82. doi: 10.5152/TJAR.2016.0011. [PubMed: 28058136].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments